Background: Treatment of cervical intraepithelial neoplasia is very important since if it remains untreated, it may progress to cervical cancer. It is usually treated with excisional surgery. This study aimed to find the factors affecting the cure rate of cervical intraepithelial neoplasia recurrence after surgery using defective models. Study design: A retrospective cohort study. Methods: Excisional surgery was performed on 307 patients with high-grade cervical intraepithelial neoplasia, from 2009 to 2017. The patients were followed up until recurrence based on histopathology report. Hematologic factors were measured before surgery. The cure rates were estimated using defective models with a Gamma frailty term and the results were compared. Results: Neutrophil-to-lymphocyte ratio (NLR) (P<0.001) and excised mass size (P<0.001) had significant impacts on cure rates, and their cut-off values were 1.9 (P<0.001) and 15 mm2 (P<0.001), respectively. Patients with lower neutrophil-to-lymphocyte ratios and larger excised tissues had higher cure rates. Defective 3-parameter Gompertz distribution with gamma frailty term had the best fit to the data, and its estimated cure rates were 98% among patients with an excised mass size of >15 mm2 and NLR of <1.9, 84% among patients with an excised mass size of >15 mm2 and NLR of >1.9, 79% among patients with an excised mass size of <15 mm2 and NLR of <1.9, and 30% among patients with an excised mass size of <15 mm2 and NLR of >1.9. Conclusion: Cervical intraepithelial neoplasia must be identified and treated before its progress. Excision of more tissues during excisional surgery, especially when the NLR of the patient is high, can help to prevent cervical intraepithelial neoplasia recurrence.

Background & Objective: Endometrial cancer is one of the most common gynecologic malignancies in developed countries. Survival rate in metastatic endometrial adenocarcinoma recurrence is reduced, and treatment in these patients is mostly palliative. One of the therapeutic options in the endometrial adenocarcinoma recurrence is hormone therapy. The expected response to the hormonal treatment is about 10-20%. Case Report: This is a case report from 57-year-old woman suffering from stage IA-Grade 1 endometrial cancer, who had vaginal carcinoma recurrence with liver and pulmonary metastasis 5.5 years after the initial treatment. Due to positive hormone receptor and the pathological profile of the tumor, hormone therapy with tamoxifen and megestrol was started. The treatment evaluation revealed complete response within five months with clearance of lung and liver metastatic lesions. There is no evidence of disease and metastases in the patient's examination and imaging after 3 years of starting hormone therapy. Conclusion: In the case of well-differentiated recurrent and metastatic endometrial cancer, good response to the hormone therapy by the least complications might be achieved.

Background evaluated the ro Neoplasia (CIN Methods: In indications for Positive VIA, symptoms/sign Results: Out due to abnorma VIA and Pap s clinical sympt symptoms/sign Conclusion: can increase th addition to or a